{"id":"myl-1701p","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Splenomegaly"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MYL-1701P is a pegylated granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their proliferation and differentiation into neutrophils. By increasing circulating neutrophil counts, it reduces the duration and severity of chemotherapy-induced neutropenia, thereby decreasing infection risk in cancer patients receiving myelosuppressive chemotherapy.","oneSentence":"MYL-1701P is a biosimilar of pegfilgrastim that stimulates neutrophil production to prevent chemotherapy-induced neutropenia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:27.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy"}]},"trialDetails":[{"nctId":"NCT03610646","phase":"PHASE3","title":"Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2018-08-23","conditions":"Diabetic Macular Edema","enrollment":355},{"nctId":"NCT04674800","phase":"PHASE3","title":"Extension Study of MYL-1701P-3001 for Safety and Efficacy","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2020-11-23","conditions":"Diabetic Macular Edema","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MYL-1701P","genericName":"MYL-1701P","companyName":"Mylan Pharmaceuticals Inc","companyId":"mylan-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MYL-1701P is a biosimilar of pegfilgrastim that stimulates neutrophil production to prevent chemotherapy-induced neutropenia. Used for Chemotherapy-induced neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}